OPKO Health (OPK) vs Savara (SVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Savara (SVRA) has outperformed OPKO Health (OPK) over the past year, gaining 39.2% versus a loss of 11.6%. Over five years, SVRA leads with a +274.4% price change compared with -63.2% for OPK. OPKO Health is the larger company by market cap ($1.03 billion vs $1.01 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OPK | SVRA |
|---|---|---|
| Share price | $1.38 | $4.93 |
| Market cap | $1.03B | $1.01B |
| 1-day change | +0.80% | +2.07% |
| YTD return | +8.73% | -19.90% |
| 1-year return | -11.61% | +39.19% |
| 5-year return | -63.17% | +274.42% |
| EPS (TTM) | $-0.09 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.75 | $7.01 |
| 52-week low | $0.98 | $3.35 |
| Distance from 52-week high | -21.09% | -29.62% |
| Analyst consensus | none | none |
| Avg. price target upside | +217.16% | +124.34% |
| Average volume | 3.35M | 1.83M |
| Shares outstanding | 746.33M | 205.46M |
| Employees | 2,275 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SVRA has outperformed OPK by 50.8 percentage points over the past year.
About OPKO Health
OPK stock →OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,275 employees
About Savara
SVRA stock →Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
OPK vs SVRA FAQ
Which is bigger, OPKO Health or Savara?
OPKO Health (OPK) is larger, with a market capitalization of $1.03B compared with $1.01B for Savara (SVRA).
Which stock has performed better over the past year, OPK or SVRA?
SVRA returned +39.19% over the past 12 months, compared with -11.61% for OPK (price return, excluding dividends). Past performance does not predict future results.
Are OPKO Health and Savara in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.